p 53 Expression in Non - Small Cell Lung Cancer: Its relationship to the clinical prognostic factor and smoking history.
- Author:
Moon Kyung KIM
;
Han Kyeom KIM
;
In Sun KIM
;
Joung Ho HAN
;
Seung Jae HUH
;
Yong Chan AHN
;
Dae Yong KIM
;
Young Mok SHIM
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
p53;
Smoking;
Ki-67
- MeSH:
Adenocarcinoma;
Carcinoma, Large Cell;
Carcinoma, Non-Small-Cell Lung;
Carcinoma, Squamous Cell;
Genes, p53;
Humans;
Immunohistochemistry;
Lung Neoplasms;
Male;
Radiotherapy, Adjuvant;
Small Cell Lung Carcinoma*;
Smoke*;
Smoking*
- From:Journal of the Korean Cancer Association
1999;31(6):1219-1226
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: p53 mutations are one of the most common genetic alterations in human lung cancer. Although the prognostic value of mutant p53 is still debated, it is widely accepted as a relatively early genetic event in the development and progression of lung cancer. Moreover, there are growing reports about an association between smoking and p53 mutation, suggesting that the p53 gene could be a target of the smoking associated carcino- genesis in the lung cancer. MATERIALS AND METHODS: Surgically resected 89 primary non-small cell lung cancers were obtained from May of 1995 to May of 1997. p53 expression and Ki-67 expression were measured by immunohistochemistry, and each p53 expression and smoking amount were compared with Ki-67 expression and other clinical prognostic factors. RESULTS: Positive p53 expressions were found in 52 (58%) specimens, including 38 (69%) squamous cell carcinomas, 11 (39%) adenocarcinomas, and 3 (50%) large cell carcinomas, and closely associated with male and squamous cell carcinoma. Also close correlation was observed between smoking amount and p53 expression by the regression analysis. But p53 and Ki-67 expression showed no associations in pathologic stage and survival, and there was no association between p53 expression and survival after adjuvant radiotherapy. CONCLUSION: Smoking seems to affect p53 mutations in non-small cell lung cancer, and additional efforts are needed to evaluate the carcinogesis of lung cancer.
